Therapy Areas: Inflammatory Diseases
Aldeyra Therapeutics Enrolls First Patient in Phase 2b Clinical Trial of Reproxalap in Dry Eye Disease
1 February 2018 - - Lexington, Massachusetts-based aldehyde-related disease specialist Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has enrolled the first patient in a Phase 2b clinical trial of topical ocular reproxalap for the treatment of dry eye disease (DED), the company said.
The Phase 2b clinical trial will test two concentrations of topical reproxalap (0.1% and 0.25%) against vehicle over 12 weeks of treatment in 300 patients with moderate dry eye disease.
Consistent with the Phase 2a clinical trial, endpoints will include standard signs and symptoms characteristic of DED.
Reproxalap and other product candidates generated from Aldeyra's aldehyde trap platform sequester and facilitate the degradation of pro-inflammatory aldehyde mediators, a class of small molecule therapeutic targets that are elevated in DED patients.
Aldeyra Therapeutics a biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases, in the US and internationally.
It is devoted to inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules.